Investor deep dive
Pharmaxis well funded as potential partners assess its anti‐fibrotic mechanisms
Pharmaxis expects an FDA decision on Bronchitol mid-year after positive committee recommendation
Quick facts: Pharmaxis Ltd
Market Cap: $73.01 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE